On July 14, 2026, ClinicalTrials.gov listed an update to a Phase 2 trial involving insulin lispro. The study, registered as NCT04542148, is titled "Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes." Its current status is listed as active, not recruiting. This designation means the trial is ongoing but is no longer enrolling new participants at this time. The trial is registered as a Phase 2 study. No results have been posted with this update, and no outcome data is included in the event record. The trial focuses on glycemic control in pregnant women with pregestational and gestational diabetes following antenatal corticosteroid administration, according to its registered title. Insulin lispro remains an approved compound, and this update reflects only the trial's recruitment and status change as of the date listed. No efficacy or safety conclusions can be drawn from a status change alone. Further updates may be posted to the registry as the trial progresses. Readers seeking more detail can consult the official ClinicalTrials.gov record for the complete protocol and eligibility history. For general background on insulin lispro, see the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT04542148"]